Curis, Inc. (CRIS) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to QRIS's second quarter 2025 business update call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After the company's prepared remarks, call participants will have an opportunity to ask questions. To ask a question, you may press star, then one on your touchtone phone. to withdraw your question, please press star, then two. Please be advised this call is being recorded today, Tuesday, August 5th, 2025. I would now like to turn the conference over to Diantha Duvall, QRIS's Chief Financial Officer. Diantha, please go ahead. Thank you, and welcome to QRIS's second quarter 2025 business update call. Before we begin, I would like to encourage everyone to go to the investor section of our website at www.keras.com to find our second quarter 2025 business update press release and related financial tables. I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectation and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings. Joining me on today's call are Jim Denser, President and Chief Executive Officer, Jonathan Zun, Chief Development Officer, and Dr. Ahmed Hamdi, Chief Medical Officer. We will also be available for a question and answer period at the end of our call. I'd now like to turn the call over to Jim. Thank you, Dantha. Good morning, everyone. and welcome to QRIS's second quarter business update call. We continue to make steady progress in our Take Aim Lymphoma Study, which is evaluating emavucirtib in combination with ibrutinib in patien...